Senesco Technologies Inc. (ELOX)

Senesco Technologies Inc. (ELOX) is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Senesco Technologies Inc. (ELOX) is not a good value stock. Senesco Technologies Inc. (ELOX) is a mediocre stock to choose.
Log in to see more information.
Eloxx Pharmaceuticals, Inc. engages in the development of novel ribonucleic acid modulating drug can...

News

Comparing Eloxx Pharmaceuticals (NASDAQ:ELOX) & BioCryst Pharmaceuticals (NASDAQ:BCRX)
Comparing Eloxx Pharmaceuticals (NASDAQ:ELOX) & BioCryst Pharmaceuticals (NASDAQ:BCRX)

Ticker Report Eloxx Pharmaceuticals (NASDAQ:ELOX Get Free Report) and BioCryst Pharmaceuticals (NASDAQ:BCRX Get Free Report) are both small-cap medical companies, but which is the better...\n more…

Eloxx Pharmaceuticals reports results of patient biopsy assessment by NIPOKA
Eloxx Pharmaceuticals reports results of patient biopsy assessment by NIPOKA

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinica
Eloxx Pharmaceuticals Reports Additional Confirmation that All Nonsense Mutation Alport Syndrome Patients Treated with ELX-02 in Phase 2 Study had Improvement in Kidney Morphology and Clinica

Globe Newswire Podocyte Exact Morphology Procedure Results\n\n Podocyte Exact Morphology Procedure Results\n\nELX-02 treatment improved podocyte foot process effacement in all three patients by an...\n more…

Financial Contrast: Novozymes A/S (OTCMKTS:NVZMY) and Eloxx Pharmaceuticals (NASDAQ:ELOX)
Financial Contrast: Novozymes A/S (OTCMKTS:NVZMY) and Eloxx Pharmaceuticals (NASDAQ:ELOX)

Zolmax Novozymes A/S (OTCMKTS:NVZMY Get Free Report) and Eloxx Pharmaceuticals (NASDAQ:ELOX Get Free Report) are both basic materials companies, but which is the better investment? We will...\n more…

Eloxx Pharmaceuticals prices $2M stock offering
Eloxx Pharmaceuticals prices $2M stock offering

Seeking Alpha - Healthcare Eloxx Pharmaceuticals prices $2M stock offering...\n more…

Eloxx Pharmaceuticals to sell 380,590 shares at $5.255 per share
Eloxx Pharmaceuticals to sell 380,590 shares at $5.255 per share

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…